Stock Scorecard



Stock Summary for BioNTech SE (BNTX) - $95.40 as of 3/28/2025 2:31:06 PM EST

Total Score

9 out of 30

Safety Score

49 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BNTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BNTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BNTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BNTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BNTX (49 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BNTX

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday - Ascentage Pharma Group ( NASDAQ:AAPG ) , Abacus Global Management ( NASDAQ:ABL ) 3/28/2025 1:52:00 PM
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - CureVac ( NASDAQ:CVAC ) 3/28/2025 12:58:00 PM
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update 3/27/2025 11:30:00 AM
Looking At BioNTech's Recent Unusual Options Activity - BioNTech ( NASDAQ:BNTX ) 3/26/2025 8:01:00 PM
RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032, Globally, at 9.4% CAGR: Verified Market Research® 3/17/2025 2:00:00 PM
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying 3/15/2025 11:15:00 AM
BioNTech Se ( BNTX ) Q4 2024 Earnings Call Transcript 3/10/2025 7:15:00 PM
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations - BioNTech ( NASDAQ:BNTX ) 3/10/2025 2:06:00 PM
BioNTech Surpasses Q4 Revenue Estimates 3/10/2025 12:42:00 PM
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory - Mission Produce ( NASDAQ:AVO ) , American Public Education ( NASDAQ:APEI ) 3/10/2025 11:29:00 AM

Financial Details for BNTX

Company Overview

Ticker BNTX
Company Name BioNTech SE
Country USA
Description BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2024
Next Earnings Date 5/16/2025

Stock Price History

Last Day Price 95.40
Price 4 Years Ago 252.01
Last Day Price Updated 3/28/2025 2:31:06 PM EST
Last Day Volume 722,348
Average Daily Volume 855,932
52-Week High 131.49
52-Week Low 76.53
Last Price to 52 Week Low 24.66%

Valuation Measures

Trailing PE N/A
Industry PE 53.93
Sector PE 40.10
5-Year Average PE 29.48
Free Cash Flow Ratio 2.35
Industry Free Cash Flow Ratio 18.14
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 7.45
Total Cash Per Share 40.68
Book Value Per Share Most Recent Quarter 80.89
Price to Book Ratio 1.10
Industry Price to Book Ratio 11.03
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 8.37
Industry Price to Sales Ratio Twelve Trailing Months 59.91
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 239,971,000
Market Capitalization 22,893,233,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date 6/2/2022
Previous Dividend Amount 0.0000
Current Dividend Amount 2.1322
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 1
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -43.20%
Annual Earnings Growth -171.51%
Reported EPS 12 Trailing Months -2.98
Reported EPS Past Year -2.81
Reported EPS Prior Year 3.83
Net Income Twelve Trailing Months -673,885,366
Net Income Past Year -665,300,000
Net Income Prior Year 930,300,000
Quarterly Revenue Growth YOY -19.50%
5-Year Revenue Growth 90.87%
Operating Margin Twelve Trailing Months 13.30%

Balance Sheet

Total Cash Most Recent Quarter 9,761,900,000
Total Cash Past Year 9,761,900,000
Total Cash Prior Year 11,663,700,000
Net Cash Position Most Recent Quarter 9,547,200,000
Net Cash Position Past Year 9,547,200,000
Long Term Debt Past Year 214,700,000
Long Term Debt Prior Year 191,000,000
Total Debt Most Recent Quarter 214,700,000
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 0.99
Total Stockholder Equity Past Year 19,411,100,000
Total Stockholder Equity Prior Year 20,245,900,000
Total Stockholder Equity Most Recent Quarter 19,411,100,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -210,021,584
Free Cash Flow Per Share Twelve Trailing Months -0.88
Free Cash Flow Past Year -244,600,000
Free Cash Flow Prior Year 4,665,900,000

Options

Put/Call Ratio 0.76
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -4.56
MACD Signal -4.51
20-Day Bollinger Lower Band 95.55
20-Day Bollinger Middle Band 113.09
20-Day Bollinger Upper Band 130.64
Beta 0.31
RSI 35.21
50-Day SMA 102.70
150-Day SMA 117.35
200-Day SMA 146.63

System

Modified 3/28/2025 7:35:12 PM EST